• Publications
  • Influence
COVID-19-associated acute kidney injury: consensus report of the 25th Acute Disease Quality Initiative (ADQI) Workgroup
This Consensus Statement from the Acute Disease Quality Initiative provides recommendations for the diagnosis, prevention and management of COVID-19 AKI and for areas of future research, with the aim of improving understanding of the underlying processes and outcomes for patients with CO VID- 19 AKI.
Changing incidence of glomerular diseases in adults.
A longitudinal study of uremic pruritus in hemodialysis patients.
This first longitudinal study of uremic pruritus describes key features of UP and its effect on HR-QOL and develops assessment instruments that are easily used, are responsive to changes in UP intensity, and should facilitate clinical evaluation and research to meet the needs of afflicted patients.
Resistance training improves strength and functional measures in patients with end-stage renal disease.
Resistance training can be used safely to increase strength and functional capacity in stable hemodialysis patients.
Executive summary of the KDIGO Controversies Conference on Supportive Care in Chronic Kidney Disease: developing a roadmap to improving quality care.
The KDIGO Controversies Conference on Supportive Care in CKD reviewed the current state of knowledge in order to define a roadmap to guide clinical and research activities focused on improving the outcomes of people living with advanced CKD, including those on dialysis.
Predicting six-month mortality for patients who are on maintenance hemodialysis.
An integrated 6-mo prognostic tool was developed and validated for the hemodialysis population and may be of value for researchers and clinicians to improve end-of-life care by providing more accurate prognostic information.
Advance care planning: a qualitative study of dialysis patients and families.
This study's findings may inform clinical practice and will be useful in designing prospective intervention studies to improve patient and family experiences at the end of life.
Doxercalciferol safely suppresses PTH levels in patients with secondary hyperparathyroidism associated with chronic kidney disease stages 3 and 4.
Doxercalciferol is safe and effective in controlling secondary hyperparathyroidism of patients with CKD stages 3 and 4 in a randomized, double-blinded, placebo-controlled, multicenter trial.
Renal palliative care.
The field of nephrology is shifting from an exclusive focus on increasing survival to one that provides greater attention to quality of life and there is an opportunity to integrate many of the advances of palliative medicine into the comprehensive treatment of these patients.